Australia markets close in 1 hour 57 minutes
  • ALL ORDS

    7,601.30
    -89.40 (-1.16%)
     
  • ASX 200

    7,296.30
    -87.90 (-1.19%)
     
  • AUD/USD

    0.7301
    +0.0012 (+0.17%)
     
  • OIL

    76.11
    +0.66 (+0.87%)
     
  • GOLD

    1,749.80
    -2.20 (-0.13%)
     
  • BTC-AUD

    58,422.66
    -2,366.16 (-3.89%)
     
  • CMC Crypto 200

    1,057.15
    -44.37 (-4.03%)
     
  • AUD/EUR

    0.6241
    +0.0017 (+0.27%)
     
  • AUD/NZD

    1.0401
    +0.0019 (+0.19%)
     
  • NZX 50

    13,214.41
    -13.29 (-0.10%)
     
  • NASDAQ

    15,204.83
    -124.85 (-0.81%)
     
  • FTSE

    7,063.40
    +11.92 (+0.17%)
     
  • Dow Jones

    34,869.37
    +71.37 (+0.21%)
     
  • DAX

    15,573.88
    +42.13 (+0.27%)
     
  • Hang Seng

    24,561.75
    +352.97 (+1.46%)
     
  • NIKKEI 225

    30,132.53
    -107.53 (-0.36%)
     

Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP

·3-min read

BERWYN, Pa., August 05, 2021--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel®), and has immediately begun commercialization activity.

Isoproterenol Hydrochloride Injection USP is indicated for:

  • mild or transient episodes of heart block that do not require electric shock or pacemaker therapy;

  • for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation);

  • for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available;

  • for bronchospasm occurring during anesthesia; and

  • as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

"We are pleased to add Isoproterenol Hydrochloride Injection USP to our generics portfolio, this product brings long term value to patients and customers in our target markets," stated Daniel Carbery, President and CEO of Amring. "We look forward to realizing the benefits of this, and other product launches and future business development activities in 2021."

About Amring Pharmaceuticals Inc.

Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of SEVER Life Sciences B.V., a global private specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies, and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

About SEVER Life Sciences B.V.

SEVER Life Sciences B.V. is a global private specialty pharmaceutical holding company committed to helping people around the world live better lives. Headquartered in the Netherlands, SEVER Life Sciences B.V. unites 4 separate pharmaceutical businesses, Nordic Pharma, Amring USA, Izvarino, and SEVER Pharma Solutions (QPharma and Disphar). They cover an interesting and diverse range of pharmaceutical products, business models, markets, and capabilities. SEVER has been created to leverage this diversity to provide better access to pharmaceutical products, improve overall efficiency between these diverse businesses and create value for its shareholders.

Safe Harbor

This press release contains forward-looking statements, including, without limitation, statements related to Amring’s business developments and the implementation of Amring’s strategic initiatives. Because these statements reflect Amring’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring’s business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805006159/en/

Contacts

Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
610-285-7137
Marina.volin@amringpharma.com

SEVER Life Sciences BV
Aernout de Bruijne
Director of Finance and Operations Planning
+31 6 207 18 634
Aernout.debruijne@severlifesciences.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting